CHRS
Price
$1.50
Change
+$0.05 (+3.45%)
Updated
Sep 26 closing price
Capitalization
174.34M
44 days until earnings call
FBRX
Price
$13.84
Change
-$0.41 (-2.88%)
Updated
Sep 26 closing price
Capitalization
172.07M
Interact to see
Advertisement

CHRS vs FBRX

Header iconCHRS vs FBRX Comparison
Open Charts CHRS vs FBRXBanner chart's image
Coherus Oncology
Price$1.50
Change+$0.05 (+3.45%)
Volume$1.57M
Capitalization174.34M
Forte Biosciences
Price$13.84
Change-$0.41 (-2.88%)
Volume$111.42K
Capitalization172.07M
CHRS vs FBRX Comparison Chart in %
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. FBRX commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a StrongBuy and FBRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (CHRS: $1.50 vs. FBRX: $13.84)
Brand notoriety: CHRS and FBRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 110% vs. FBRX: 141%
Market capitalization -- CHRS: $174.34M vs. FBRX: $172.07M
CHRS [@Biotechnology] is valued at $174.34M. FBRX’s [@Biotechnology] market capitalization is $172.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 1 FA rating(s) are green whileFBRX’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 1 green, 4 red.
  • FBRX’s FA Score: 0 green, 5 red.
According to our system of comparison, CHRS is a better buy in the long-term than FBRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while FBRX’s TA Score has 5 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 4 bearish.
  • FBRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both CHRS and FBRX are a good buy in the short-term.

Price Growth

CHRS (@Biotechnology) experienced а -6.83% price change this week, while FBRX (@Biotechnology) price change was +2.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

CHRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($174M) and FBRX($172M) have the same market capitalization . CHRS YTD gains are higher at: 8.696 vs. FBRX (-39.058). CHRS has higher annual earnings (EBITDA): 88.2M vs. FBRX (-43.64M). CHRS has more cash in the bank: 238M vs. FBRX (106M). CHRS has higher revenues than FBRX: CHRS (272M) vs FBRX (0).
CHRSFBRXCHRS / FBRX
Capitalization174M172M101%
EBITDA88.2M-43.64M-202%
Gain YTD8.696-39.058-22%
P/E Ratio2.83N/A-
Revenue272M0-
Total Cash238M106M225%
Total Debt41MN/A-
FUNDAMENTALS RATINGS
CHRS vs FBRX: Fundamental Ratings
CHRS
FBRX
OUTLOOK RATING
1..100
803
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
97
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
598
PRICE GROWTH RATING
1..100
3738
P/E GROWTH RATING
1..100
8445
SEASONALITY SCORE
1..100
n/a43

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHRS's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for FBRX (97) in the null industry. This means that CHRS’s stock grew somewhat faster than FBRX’s over the last 12 months.

CHRS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as FBRX (100) in the null industry. This means that CHRS’s stock grew similarly to FBRX’s over the last 12 months.

CHRS's SMR Rating (5) in the Biotechnology industry is significantly better than the same rating for FBRX (98) in the null industry. This means that CHRS’s stock grew significantly faster than FBRX’s over the last 12 months.

CHRS's Price Growth Rating (37) in the Biotechnology industry is in the same range as FBRX (38) in the null industry. This means that CHRS’s stock grew similarly to FBRX’s over the last 12 months.

FBRX's P/E Growth Rating (45) in the null industry is somewhat better than the same rating for CHRS (84) in the Biotechnology industry. This means that FBRX’s stock grew somewhat faster than CHRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSFBRX
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 5 days ago
74%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
64%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RAFA0.05N/A
+2.06%
Rafarma Pharmaceuticals, Inc. (WY)
CKHGY101.810.27
+0.27%
Capitec Bank Holdings Ltd
DCHIF0.38N/A
N/A
Digital China Holdings Ltd.
KOTMY15.30N/A
N/A
Koito Manufacturing Co., Ltd.
GGLDF0.31N/A
-1.47%
Getchell Gold Corporation

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+3.45%
XENE - CHRS
40%
Loosely correlated
+4.00%
XNCR - CHRS
37%
Loosely correlated
+12.00%
RXRX - CHRS
34%
Loosely correlated
+1.94%
DNA - CHRS
34%
Loosely correlated
+2.22%
SRRK - CHRS
33%
Loosely correlated
+12.35%
More

FBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, FBRX has been loosely correlated with QSI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if FBRX jumps, then QSI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FBRX
1D Price
Change %
FBRX100%
-2.88%
QSI - FBRX
34%
Loosely correlated
-1.32%
CLNN - FBRX
32%
Poorly correlated
+0.09%
CHRS - FBRX
29%
Poorly correlated
+3.45%
APLM - FBRX
28%
Poorly correlated
N/A
OCGN - FBRX
27%
Poorly correlated
-3.95%
More